摘要:
The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alk yl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH, n is 0 and m+o =2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.
摘要:
The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
摘要:
The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
摘要:
The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1 C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1 C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C- 4C)alkyl, optionally halogenated (1 C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1 C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1 C-4C)alkoxy or optionally halogenated aryl(1 C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1 C-4C)alkyl, or R6 is optionally halogenated (1 C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1 C-4C)alkyl or optionally halogenated (1 C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.